Estradiol Gel (Divigel/Elestrin) vs Duavee: Which Works Better for Menopause?

Why This Comparison Matters to You

There is no published randomized trial that put estradiol gel and Duavee in the same room and measured them directly against each other. Full stop. What does exist are well-designed, placebo-controlled trials for each product separately, and those trials give us enough to make a clinically useful comparison across efficacy, safety, and fit for specific women.

If you have been told to "pick a menopause hormone therapy" and handed a brochure, you already know how little that brochure tells you about the differences that actually affect your day-to-day life. This article is the longer, more specific version of that conversation.

What Each Drug Actually Is

Estradiol gel, sold as Divigel (0.1% estradiol gel applied once daily) and Elestrin (0.06% estradiol gel), delivers bioidentical 17-beta estradiol through the skin. The estradiol absorbs directly into circulation, bypassing first-pass liver metabolism. If your uterus is intact, you must add a progestogen to protect the endometrium from estrogen-driven hyperplasia.

Duavee pairs conjugated estrogens (CE) 0.45 mg with bazedoxifene (BZA) 20 mg. Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an antagonist in uterine and breast tissue. That SERM activity replaces the progestogen, so Duavee can be used in women with an intact uterus without adding a separate progestogen or progesterone. The FDA approved Duavee in 2013 specifically for this indication in postmenopausal women with a uterus.

The Estrogen in Each Is Different

This distinction matters more than most branded marketing suggests. Estradiol gel delivers bioidentical 17-beta estradiol, the same molecule your ovaries produced before menopause. Duavee delivers conjugated estrogens, a mixture of estrone sulfate, equilin sulfate, and other conjugated equine or plant-derived estrogens. The two are not biologically identical, and their receptor-binding profiles differ in ways that may affect symptom response and risk in individual women.

Hot Flash Efficacy: What the Trials Show

Both products reduce the frequency and severity of moderate-to-severe vasomotor symptoms (VMS) compared to placebo. The effect sizes are meaningful, but the study designs are different enough that direct numerical comparison is misleading.

Estradiol Gel Trial Data

Divigel's key trial showed statistically significant reductions in daily hot-flash frequency versus placebo at weeks 4 and 12 across three doses (0.25 g, 0.5 g, and 1.0 g daily). The 0.5 g dose (the most commonly prescribed starting dose) produced serum estradiol levels in the range of 40 to 50 pg/mL, which is associated with symptom control in most women. Elestrin's prescribing-information data show similar reductions with 0.87 g applied daily.

Transdermal delivery matters here. Because the gel bypasses hepatic first-pass metabolism, you get relatively steady serum estradiol levels without the peak-and-trough pattern seen with oral estrogen. That pharmacokinetic stability may translate to fewer hormone-fluctuation symptoms.

Duavee (SMART Trial Program) Data

The SMART (Selective estrogens, Menopause, And Response to Therapy) trial program is the core evidence base for Duavee. SMART-2 was a 12-week, randomized, double-blind, placebo-controlled trial of CE 0.45 mg/BZA 20 mg versus CE 0.625 mg/BZA 20 mg versus placebo in 318 postmenopausal women with at least 7 moderate-to-severe hot flashes per day at baseline. Both active doses significantly reduced mean daily hot-flash frequency and severity compared to placebo by week 4 and week 12. The CE 0.45 mg/BZA 20 mg dose (the approved Duavee formulation) reduced mean hot-flash frequency by approximately 74% from baseline by week 12 versus a 51% reduction in the placebo group.

SMART-5 extended follow-up to 12 months and confirmed durable symptom relief alongside bone mineral density preservation compared to placebo, with no significant endometrial hyperplasia signal in the CE/BZA groups. That endometrial safety data is central to Duavee's regulatory approval.

Side-by-Side Snapshot

| Outcome | Estradiol Gel | Duavee (CE/BZA) | |---|---|---| | Hot flash frequency reduction vs placebo | Significant at 4 and 12 weeks | ~74% reduction from baseline at 12 weeks (SMART-2) | | Duration of controlled trial data | 12 weeks (key) | 12 months (SMART-5) | | Endometrial protection | Requires separate progestogen | Built-in via bazedoxifene | | Bioidentical estrogen | Yes (17-beta estradiol) | No (conjugated estrogens) | | Breast tissue stimulation | Yes; monitor per standard HRT guidance | May be lower; BZA may partially antagonize CE in breast | | Direct head-to-head trial | Not available | Not available |

Bone Mineral Density: Which Protects Better?

Postmenopausal bone loss accelerates sharply in the first three to five years after your final period. Both agents address this, but the quality and duration of trial data differ.

Estradiol Gel and Bone

Transdermal estradiol at doses that achieve serum estradiol above approximately 30 pg/mL consistently preserves or increases BMD at the lumbar spine and hip in postmenopausal women. This is well-established class-level evidence for transdermal estradiol; the gel formulations share this effect. The FDA-approved indication for Divigel and Elestrin includes prevention of postmenopausal osteoporosis, though both are indicated for VMS as the primary indication with osteoporosis prevention as secondary.

Duavee and Bone (SMART-5)

SMART-5 demonstrated statistically significant increases in lumbar spine BMD with CE 0.45 mg/BZA 20 mg versus placebo over 12 months, with a mean treatment difference of approximately 1.5% at the lumbar spine. This is a direct trial result, not an extrapolation from class data. Bazedoxifene itself carries bone-protective SERM activity (it is approved as a standalone osteoporosis treatment in Europe), so the bone benefit in Duavee may be additive from both the estrogen and the SERM components.

For women with established osteoporosis or very high fracture risk, neither agent is a first-line bone-specific treatment. Bisphosphonates or denosumab would typically be prioritized. If your main reason for HRT is bone protection alone, this matters.

VTE Risk: A Meaningful Safety Difference

This is one area where the route-of-delivery difference between the two products creates a real, clinically significant distinction.

Oral estrogens increase venous thromboembolism (VTE) risk by approximately two-fold compared to non-use. Transdermal estradiol appears to carry a substantially lower risk. A large observational study published in the BMJ found that transdermal estradiol was not associated with increased VTE risk at doses below 50 mcg/day, while oral estrogens were, regardless of progestogen type. Estradiol gel delivers estradiol transdermally and thus shares this lower-risk profile.

Duavee uses oral conjugated estrogens. The VTE data for CE/BZA specifically are more limited than the extensive oral estrogen VTE literature, and CE at 0.45 mg is a lower dose than most historical oral HRT trials used. No large observational study has specifically quantified VTE risk for CE 0.45 mg/BZA 20 mg in the way that transdermal data have been quantified. The product label includes a VTE warning consistent with oral estrogen products.

For women with personal or strong family history of VTE, or with obesity (BMI >30), estradiol gel's transdermal delivery may be a better fit from a thrombosis-risk standpoint.

Sex-Specific Physiology: How Your Hormonal Status Changes the Picture

Perimenopause vs. Postmenopause

Duavee is approved specifically for postmenopausal women with a uterus. If you are in perimenopause, still having irregular cycles, or less than 12 months from your last period, Duavee is not the appropriate choice. Perimenopause involves fluctuating and sometimes elevated estradiol levels; adding more estrogen without reliable cycle suppression creates unpredictable hormonal layering.

Estradiol gel can technically be used in perimenopausal women, though dosing is more individualized because endogenous production is still variable. Most clinicians start gel in the postmenopausal window when ovarian estradiol production has reliably ceased.

Women Without a Uterus

If you have had a hysterectomy, Duavee has no advantage over estradiol gel. The entire rationale for CE/BZA is endometrial protection as a progestogen replacement. Without a uterus, estradiol gel alone (no progestogen needed) is simpler, uses a bioidentical molecule, and has a longer track record. You would not choose Duavee over estradiol gel on efficacy grounds alone in this setting.

PCOS and Insulin Resistance

Women with a history of PCOS entering perimenopause or menopause often have underlying insulin resistance and carry higher cardiovascular metabolic risk. Transdermal estradiol does not adversely affect triglycerides or insulin sensitivity in the way that oral estrogen can, because it bypasses hepatic first-pass metabolism. Oral CE in Duavee may raise triglycerides modestly. If you have a history of PCOS with dyslipidemia or elevated triglycerides, estradiol gel is the more favorable choice based on the pharmacokinetic difference.

The following framework is not published in any single guideline but synthesizes FDA labeling, SMART trial data, and the BMJ transdermal VTE analysis into a decision structure for clinicians and patients:

Choose estradiol gel over Duavee when:

• You have had a hysterectomy (no need for built-in endometrial protection)
• You have elevated VTE risk (personal history, strong family history, BMI >30, or thrombophilia)
• You have a history of PCOS with elevated triglycerides
• You prefer a bioidentical estrogen molecule
• You want the option to titrate dose granularly (gel allows small stepwise adjustments)
• You are in perimenopause and your clinician wants to adjust dose with your cycle

Choose Duavee over estradiol gel when:

• You have an intact uterus and cannot or will not take a progestogen (progestin intolerance, personal preference, or specific contraindication)
• Progestogen side effects (mood changes, bloating, breakthrough bleeding) have made previous HRT intolerable
• You want a single pill rather than a daily gel application
• You are postmenopausal, not trying to conceive, and want a simpler regimen

Pregnancy, Lactation, and Contraception

Both estradiol gel and Duavee are contraindicated in pregnancy. This is not a nuance. Both products carry FDA Pregnancy Category X designations, meaning the risks to a fetus outweigh any possible benefit, and neither should be used by any woman who is pregnant or may become pregnant.

Estradiol Gel in Pregnancy and Lactation

Exogenous estradiol is a known teratogen in high doses and is contraindicated throughout pregnancy. Estradiol is present in breast milk; the amount transferred via transdermal gel is not fully quantified in lactating women, and use during breastfeeding is not recommended. Estradiol gel may also suppress milk production. Women who are breastfeeding should not use estradiol gel without a frank discussion with their clinician about risks to milk supply and infant exposure.

Duavee in Pregnancy and Lactation

Duavee contains bazedoxifene, a SERM. SERMs as a class cause fetal harm in animal studies, and bazedoxifene is contraindicated in pregnancy. Conjugated estrogens are similarly contraindicated. Duavee should not be used by women who are breastfeeding. The combination is approved only for postmenopausal women; by definition, this agent is not intended for any woman in her reproductive years.

Contraception Note

Women in the menopausal transition who are still having any cycles (however irregular) and using either of these products must not assume that HRT provides contraception. It does not. Ovulation can still occur in perimenopause. If there is any possibility of pregnancy, reliable contraception is required alongside HRT until you have been confirmed postmenopausal (12 consecutive months without a period, or confirmed by FSH levels in the appropriate clinical context).

Who This Is Right For (and Who It Is Not)

Best Candidates for Estradiol Gel

You are likely a good candidate for Divigel or Elestrin if you are a postmenopausal woman (or guided by a clinician in perimenopause) with moderate-to-severe hot flashes, night sweats, or genitourinary symptoms of menopause, who does not have contraindications to estrogen. Women with a history of VTE, active or recent cardiovascular disease, estrogen-dependent cancer, unexplained vaginal bleeding, or liver disease should not use estradiol gel.

Women who are good candidates:

• Postmenopausal with a uterus, willing to add a progestogen
• Postmenopausal after hysterectomy (gel alone, no progestogen)
• Women who have had poor tolerability with oral HRT due to GI effects
• Women who prefer dose flexibility
• Women with PCOS history and triglyceride concerns

Best Candidates for Duavee

Duavee is specifically for postmenopausal women with an intact uterus. If you do not have a uterus, Duavee offers you no advantage over simpler estrogen-only therapy.

Women who are good candidates:

• Postmenopausal with intact uterus and documented progestogen intolerance
• Women who prefer oral administration to topical
• Women in whom progestogen-related bleeding or mood side effects have been a significant barrier to HRT adherence
• Women who want a single agent rather than a gel-plus-progestogen combination

Women who are not candidates for Duavee:

• Women after hysterectomy (no indication for CE/BZA over simpler therapy)
• Women with active VTE or high thrombosis risk
• Women with estrogen-sensitive cancers
• Women still in perimenopause with regular or irregular cycles
• Women who are pregnant or trying to conceive

The Evidence Gap: What We Do Not Know

Women have been chronically underrepresented in cardiovascular and thrombosis trials, and most VTE risk data for estrogen products come from studies that enrolled relatively few women of color or women with complex metabolic histories. The BMJ transdermal VTE study is observational, not a randomized trial, and residual confounding is possible.

No randomized trial has directly compared estradiol gel to Duavee on any outcome. The comparison in this article rests on evidence triangulation across separate trials with different designs, populations, and follow-up durations. That is the honest state of the evidence. Extrapolating the SMART-2 hot-flash number against Divigel's key trial number as if they were head-to-head results would be misleading.

Long-term breast cancer data for CE/BZA remain less mature than the extensive literature on CE plus medroxyprogesterone acetate from the Women's Health Initiative. Whether BZA meaningfully attenuates CE's effect on breast tissue in the long term is not yet established with the same confidence as the endometrial data.

SMART-2 enrolled women with at least seven moderate-to-severe hot flashes per day. If your symptom burden is lower, your individual response may differ from trial means.

Practical Dosing and Administration Notes

Estradiol Gel Dosing

Divigel is typically started at 0.25 g or 0.5 g applied once daily to the upper thigh, alternating sides. The dose may be titrated up to 1.0 g based on symptom response and serum estradiol levels. Elestrin is started at 0.87 g (one pump) applied once daily to the upper arm. Skin contact transfer is a real concern; allow the gel to dry before skin-to-skin contact, and wash hands thoroughly after application.

If you have a uterus and are using estradiol gel, you will need a progestogen. Options include oral micronized progesterone (Prometrium), a progestin like norethindrone acetate, or a levonorgestrel IUD (Mirena). Your clinician will select the type and schedule based on your bleeding pattern preference and history.

Duavee Dosing

Duavee comes as a single fixed-dose oral tablet: CE 0.45 mg/BZA 20 mg, taken once daily. There is no dose adjustment option within the product. If the 0.45 mg CE dose does not adequately control symptoms, Duavee cannot be titrated up; switching to a different HRT formulation would be the next step. Calcium and vitamin D supplementation are recommended alongside Duavee, as the SMART trials used these as part of the study protocol for bone outcomes.

Avoid eating foods high in grapefruit content while on Duavee; bazedoxifene is metabolized via UGT1A3 and CYP3A4 pathways, and interactions with strong inhibitors of these enzymes are possible, though clinically significant interactions at the CE 0.45 mg dose are not well-documented.

What Clinicians Are Saying

The Menopause Society's 2023 position statement states that hormone therapy "remains the most effective treatment for vasomotor symptoms" and that "for women who are appropriate candidates, the benefits of HRT outweigh the risks in the early postmenopause." The statement specifically notes that transdermal estrogen is preferred over oral estrogen when VTE risk is a consideration.

The same position statement affirms that tissue-selective estrogen complexes (TSEC), the class to which Duavee belongs, represent "a reasonable option for postmenopausal women with a uterus who cannot tolerate progestogens."

Dr. Elena Vasquez, MD, WomanRx clinical reviewer and NAMS-certified menopause practitioner, comments: "In my practice, the Duavee conversation usually starts with a woman who has tried progesterone and hated how it made her feel. The mood changes, the bloating, the return of PMS-like symptoms in menopause. For her, CE/BZA is genuinely life-changing. But for a woman with a history of a blood clot, or someone who wants bioidentical estrogen and is comfortable using a gel, transdermal estradiol with micronized progesterone remains the approach I reach for first."